Generic Semaglutide: What Canada's G7 First Shows So Far

Canada became the first G7 country to approve a generic version of semaglutide, the drug in Ozempic and Wegovy, in April 2026 ^[1]. It got there early because a key patent lapsed, not because the drug's protection ran out on schedule ^[2][3]. Six months on, the Canadian launch and India's larger one show that price falls quickly, but supply and quality decide who can actually sell.

This explainer covers how the opening happened, how Health Canada reviews a generic peptide, who has entered, and what the first months of data show. It ends with what the shift means for people in manufacturing, quality, regulatory affairs and business development.

How Canada ended up first

Semaglutide is a big product in Canada. Ozempic was the country's best-selling drug in 2025, with $2.9 billion in sales, more than three times the next drug on the list ^[2]. Commentators have also described Canada as the world's second-largest semaglutide market ^[3].

The opening came from a missed fee. In 2019, Novo Nordisk did not pay a CAD 250 maintenance fee on Canadian patent CA 2601784 ^[2]. The patent office allowed a further year to pay the missed fee plus a late fee, a total of CAD 450, and Novo did not pay ^[3]. The patent database shows the last maintenance payment on October 23, 2018, and the period for reversal ending on August 31, 2020 ^[2]. Once a Canadian patent lapses this way, it cannot be revived ^[3].

The patent alone would have expired on March 20, 2026 ^[2]. What it carried was more valuable. Canada grants a certificate of supplementary protection (CSP), a form of patent term extension of up to two years ^[3]. The semaglutide CSP was tied to this patent and would have run to March 20, 2028 ^[2]. With the patent gone, the certificate no longer works, so Novo appears to have given up about two years of protection ^[3].

A patent was not the only barrier. Canada also protects the clinical trial data that a company files to win approval, a rule called data protection or data exclusivity. That protection kept generics out and was due to expire in 2026 ^[3].

Whether the lapse was a mistake is still debated. Novo told Fortune that all intellectual property decisions are carefully considered at a global level, and the company later described the move as a strategic choice ^[3][2]. One line of argument points to price rules. Canada's Patented Medicine Prices Review Board (PMPRB) caps the prices of patented medicines, and without the patent, Novo's Canadian prices no longer fall under that review ^[3]. The law firm that set out this argument concluded that no firm answer is possible yet ^[3].

Elsewhere in the G7, protection lasts much longer. Novo's own patent table lists active ingredient protection to 2032 in the United States and to 2031 in Japan and Europe ^[2]. Novo has settled U.S. patent litigation over Ozempic with several generic makers, including Dr. Reddy's, Apotex, Sun Pharma, Mylan and Zydus, on confidential terms ^[2].

How Health Canada reviews a generic peptide

Semaglutide sits in an unusual regulatory spot. Health Canada calls the generic versions complex synthetic products that are pharmaceutically equivalent to the brand name biologic drug ^[1]. In other words, the generic is made by chemical synthesis, while the reference product is treated as a biologic. The regulator's review checks that any differences between the products do not affect safety, efficacy or quality ^[1].

Apotex said its product went through Health Canada's standard regulatory review for peptide medicines ^[4]. That matters for planning. A peptide generic follows the generic route, not a separate biosimilar pathway, but the evidence package still has to address the extra complexity of the molecule ^[1][4].

Speed was part of Health Canada's message. It finished the review of the first submission within its 180-day target ^[1]. The clock has a catch. Time a manufacturer spends providing missing data does not count toward the target, and a second review round then begins, which extends the total ^[1]. Health Canada also says its target for generic submissions is shorter than that of many international regulators ^[1].

The queue is long. When it approved the first product in April, the department was reviewing eight other generic semaglutide submissions from different companies ^[1]. By late June, after a third approval, six others remained under review ^[5].

Who is in the Canadian market

Three approvals in the spring set the early shape of the market.

Date	Company	Reference brand	Approved use
April 28, 2026	Dr. Reddy's Laboratories	Ozempic	Type 2 diabetes in adults
May 1, 2026	Apotex (Apo-Semaglutide Injection)	Ozempic	Type 2 diabetes in adults
June 29, 2026	Apotex (Sevmia)	Wegovy	Chronic weight management, age 12 and over

The table draws on Health Canada's releases and the Apotex announcement ^[1][5][4]. The June approval was the first generic semaglutide for weight management in Canada and the third generic semaglutide the department had approved ^[5].

The companies took different routes to market. Dr. Reddy's said it makes the active pharmaceutical ingredient (API) entirely in-house, while OneSource Specialty Pharma handles the finished product ^[2]. Apotex, the largest Canadian-based drugmaker, developed its product with Orbicular Pharmaceutical Technologies ^[4]. Apotex said it would be the first Canadian generic to offer both pen formats commercially, matching every brand SKU ^[4].

Price is where generics compete. Health Canada notes that many generic medicines in Canada cost 45 to 90% less than the brand ^[1]. Dr. Reddy's launched in Canada on May 15 with a list price of about half of Novo's, according to BioPharma APAC ^[6]. These are list prices. What patients and plans pay depends on coverage and pharmacy pricing.

What the data shows

Canada's market is still young, and public sales data is thin. India offers a fuller picture, because its compound patent lapsed on March 20, 2026, and copies launched almost at once ^[6]. The same patent expired in China on the same day, but no generic had been approved there by early October ^[6].

In India, BioPharma APAC counted 12 generic makers with public launches, selling 20 brands ^[6]. The cheapest generic cost Rs 1,290 a month ^[6]. Ozempic had launched in India in December 2025 at Rs 8,800 a month for its lowest strength ^[6].

Generics took share fast. By April, they made up exactly half of India's semaglutide sales by value, Rs 44 crore of an Rs 88 crore market, citing Pharmarack data ^[6]. By volume the shift was larger: generics accounted for about 137,000 of 170,000 injectable units, or roughly four in five ^[6].

The brand owner responded with price cuts. Novo cut prices effective April 1, and the starting dose of Wegovy fell by about 48% ^[6]. Even so, BioPharma APAC found Novo's cheapest pen still cost more than four times the cheapest generic vial ^[6].

The device shapes the price as much as the molecule. Natco and Eris priced their pens at more than three times their vials of the same drug ^[6]. For generic makers, that makes fill-finish format and device supply a commercial decision, not just a technical one.

Three patterns stand out. First, price falls sharply when many makers enter at once. Second, the brand owner cuts price but keeps a premium. Third, the cheapest format is not always the one that wins share.

The supply problem: quality and capacity

A fast launch also exposed how fragile peptide supply can be. In July, Dr. Reddy's said certain batches were out of specification because of an issue with the API ^[7]. Chief executive Erez Israeli told analysts the impurity showed up in API testing of pre-validation batches during scale-up ^[7].

The company said commercial supplies would be delayed in India and would face disruptions in Canada ^[7]. It said existing inventories in both countries were not affected, and that there was no impact on patient safety or on its regulatory filings ^[7]. Dr. Reddy's said supply could resume as early as late October or early November 2026, and Israeli said that would follow only after successful validation ^[7].

The cost was real. Dr. Reddy's cut its target to 6 million to 7 million pens for the second half of its fiscal year, down from an earlier estimate of 12 million ^[7]. It had sold about 180,000 pens before the pause and took a provision of Rs 240 crore, according to BioPharma APAC ^[6]. Torrent, which sold pens made by Dr. Reddy's, recalled selected batches as a precaution ^[6][7].

The wider constraint is capacity. Neeraj Sharma, chief executive of contract manufacturer OneSource, said demand for GLP-1 drugs exposes gaps in peptide APIs, sterile fill-finish, injector devices and glass cartridges ^[7]. He said the market will be limited by supply rather than demand, and expects constraints to last at least two years ^[7]. OneSource said its capacity was fully committed, including for Canada ^[7].

For regulators and buyers, this is the trade-off. Many approvals can lower prices, but each new supplier must hold its specification at commercial scale. A batch failure at one supplier can affect several brands, because many sellers share a smaller number of makers ^[6].

What it means for people in the industry

Manufacturing and CMC. Peptide generics reward deep process control. The Dr. Reddy's case shows that problems can appear late, during scale-up, even after approval ^[7]. Teams working on peptide synthesis, purification and impurity profiling should expect close scrutiny, because the regulator's question is whether any difference from the brand matters ^[1].

Quality. Out-of-specification results, root cause work and validation now sit on the critical path of a commercial launch ^[7]. Quality leaders at generic makers and their contract partners should plan for this before launch, not after.

Regulatory affairs. Canada's generic route for a complex synthetic peptide is now proven, with three approvals in about two months ^[5]. Clock stops for missing data extend reviews, so complete, well-organized files are the fastest path ^[1]. With protection in the U.S., Japan and Europe running to 2031 or 2032, Canada is the main G7 test case for years ^[2].

Intellectual property and business development. A small unpaid fee changed the timing of a multibillion-dollar market ^[2][3]. Patent teams should treat maintenance fees and linked extensions, such as CSPs, as one system ^[3]. Deal teams should also note the supply model. In India, several brands are made by a few manufacturers through licensing ^[6].

Contract manufacturers. Demand for peptide API and sterile fill-finish capacity is high, and some partners report fully committed lines ^[7]. Device and cartridge supply may be as tight as the drug itself ^[7].

Hiring. The sources do not give job numbers. Still, the work described above points to demand for peptide chemists, process engineers, quality and validation specialists, and regulatory staff who know complex generics. If you follow these roles, our pharma jobs board lists openings in the U.S. and Canada, and PharmoniQ news tracks new approvals.

What to watch next

The next few months will show how stable the Canadian market is. Health Canada still has more generic semaglutide submissions under review, and more decisions could reshape the market ^[5]. Dr. Reddy's return to supply, possible as early as late October or early November, is the first test ^[7].

China is the other market to watch. Novo says Ozempic holds data protection there until April 2027, and the first Chinese applicant says its review has been suspended over data protection ^[6]. In the U.S., the settled litigation and 2032 patent date set a later timeline ^[2].

Key takeaways

• Canada approved the first generic semaglutide in the G7 on April 28, 2026, after a key Novo Nordisk patent lapsed over an unpaid fee ^[1][2].
• The lapse also voided a supplementary protection certificate that would have run to March 2028 ^[2][3].
• Health Canada treats generic semaglutide as a complex synthetic product and reviews it through the generic route, with a 180-day target ^[1].
• Three approvals came by late June, including the first generic for weight management, with six more submissions then under review ^[5].
• In India, generics reached half of semaglutide sales by value within weeks, and the brand owner cut prices ^[6].
• An API quality issue at Dr. Reddy's delayed supply in India and disrupted it in Canada, showing that scale-up and capacity limit the market ^[7].

References

1. Canada becomes the first G7 country to approve a generic version of semaglutide. Health Canada, Apr 28, 2026.
2. Canada approves generic semaglutide from Dr. Reddy's, a G7 first enabled by Novo Nordisk's lapsed CAD$250 patent. Drug Discovery & Development, May 13, 2026.
3. A Key Ozempic Patent Lapses in Canada: Deliberate or a Mistake?. Reddie & Grose, Oct 15, 2025.
4. Apotex becomes the first Canadian-based global pharmaceutical company to receive Health Canada approval for a generic equivalent of Ozempic. Apotex, May 1, 2026.
5. Canada approves first generic semaglutide for weight loss. Health Canada, Jun 29, 2026.
6. Semaglutide Generics, Six Months In: Every Launch in India, Every Price, and Where China Stands. BioPharma APAC, Oct 9, 2026.
7. Dr. Reddy's says API issue delays commercial supplies of its generic semaglutide. Pharma Manufacturing, Jul 10, 2026.